5 recruiting, 2 active not recruiting, 1 completed, 1 terminated. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 5, Active not recruiting 2, Completed 1, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Axi-cel: new trials by email Literature Review of Axi-cel trials Research Report on Axi-cel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma Leukapheresis, Bridging Therapy, Lymphodepletion - B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Terminated | Universität Münster | 1 | 2025-03-13 | 2025-09-04 |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma Glofitamab, Obinutuzumab, Axi-cel - B Cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-05-07 | 2026-11-03 |
| Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-11-08 | 2026-03-31 |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-05-19 | 2026-09-16 |
| Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL ARI-0001, Axi-cel - NHL, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University Medical Center Groningen | 340 | 2022-10-18 | 2026-10-05 |
| Chidamide Bridging for CAR-T Therapy Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells - Non Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 120 | 2022-05-25 | 2024-03-06 |
| Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation axicabtagene ciloleucel - B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Active not recruiting | The Lymphoma Academic Research Organisation | 62 | 2021-03-10 | 2026-03-27 |
| A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Completed | Kite, A Gilead Company | 159 | 2017-06-06 | 2025-12-23 |
Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Non-Hodgkin (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · Chinese PLA General Hospital (1) · City of Hope Medical Center (1) · Kite, A Gilead Company (1) · M.D. Anderson Cancer Center (1) · The Lymphoma Academic Research Organisation (1) · University Medical Center Groningen (1) · University of Michigan Rogel Cancer Center (1) · Universität Münster (1)
United States (6) · France (2) · Belgium (1) · China (1) · Germany (1) · Netherlands (1)
Michael Jain, MD, PhD (2) · Georg Lenz, Prof (1) · Jason Westin, MD (1) · Karamjeet S Sandhu (1) · Monalisa Ghosh (1) · Roch Houot, PhD (1) · Weidong Han, Ph.D (1)
PMID 37710005, PMID 39240498, PMID 40536814, PMID 41100801, PMID 41512176, PMID 42745632
2017 (1), 2023 (1), P30CA033572 (1)